A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Asian Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension - BaxAsia

Study identifier:D6970C00008

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Double-Blind, Randomized, Placebo-Controlled, Multicentre Study Evaluating the Efficacy and Safety of Baxdrostat in Asian Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension

Medical condition

Uncontrolled Hypertension

Phase

Phase 3

Healthy volunteers

No

Study drug

Baxdrostat, Placebo

Sex

All

Estimated Enrollment

300

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 18 Apr 2024
Estimated Primary Completion Date: 20 May 2026
Estimated Study Completion Date: 20 May 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria